HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - Bringing artificial intelligence from the laboratory to a broad spectrum of industries—particularly in the B2B market—demands that AI companies overcome a formidable set of challenges: how to precisely match complex, ever-evolving business scenarios; how to achieve scalable delivery; and how to establish a sustainable business model.Extreme Vision, based in Qingdao, Shandong, has delivered its answer through a compelling set of metrics. As of September 30, 2025, the Company had completed over 6,000 projects, recorded a product repurchase rate exceeding 80%, and served more than 100 industries, including manufacturing, energy, retail, and transportation. Revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate of 59.2%. The Company turned profitable in 2024.A Platform-based Approach to Tackling the Fragmentation ChallengeExtreme Vision was founded by three entrepreneurs born in the 1990s: Mr. Chan Chan Kit, Ms. Luo Yun, and Mr. Chen Shuo. Mr. Chan Chan Kit holds a direct stake of 16.05% in the Company and serves as its largest shareholder, legal representative, chairman of the board, executive director, and general manager. The three founders, all alumni of Sun Yat-sen University, first conceived the idea of starting a business during their undergraduate studies.“The biggest challenge in the B2B market is fragmentation,” Mr. Chan once noted. Different industries, different enterprises, and even different production processes within the same company all have vastly different AI requirements. If each scenario requires developing algorithms from scratch, the cost is prohibitive, the timeline is protracted, and scaling becomes virtually impossible. This is precisely the “B2B chasm” that many AI companies struggle to cross. Based on this insight, Extreme Vision pioneered the AI Vision Algorithm Marketplace.As of September 30, 2025, Extreme Vision’s algorithm marketplace has launched 1,517 algorithms, including 1,369 algorithms co-developed with third-party developers. Covering application scenarios in over 100 industries, the platform has served more than 3,000 customers and delivered over 6,000 projects since its establishment. Notably, the product repurchase rate has exceeded 80%, reflecting the strong standardization of its solutions and robust market recognition.Self-developed AI infrastructure empowers efficient implementation. The Company’s self-developed AI infrastructure enables efficient algorithm development and rapid solution development. On the one hand, leveraging its self-developed full-stack technology platform, Extreme Vision has built an industry-leading AI infrastructure that covers the entire lifecycle, including data annotation, model training, algorithm development, algorithm testing and inference deployment. On the other hand, the integrated tool engines within its AI development infrastructure significantly lowering the barriers to algorithm development and drastically reducing the time required for customized algorithm development.Multi-industry Implementation: Project Practice as a Driver for Healthy GrowthLeveraging its platform-based capabilities, Extreme Vision has applied its technology to real-world business scenarios across various sectors, delivering actionable and reusable solutions.In terms of industrial manufacturing, Extreme Vision deployed an EHS+AI intelligent monitoring system for CR Beer. By implementing 25 categories of risk-identification algorithms, the system accurately captures risk scenarios such as the improper wearing of safety ropes and goggles, hoisting operations, and unauthorized personnel intrusion during equipment operation. This has successfully transformed traditional passive safety management into proactive, real-time, and automated risk control.In terms of environmental and energy sectors, Extreme Vision has built an intelligent security management platform, “Halo Guard” for China Everbright Environmental Energy. Equipped with nearly 30 AI vision algorithms for safety management and control, the platform conducts real-time monitoring of high-risk operational scenarios such as unloading platforms and burning zones, significantly enhancing operational safety.In the higher education sector, Extreme Vision has jointly established the “Artificial Intelligence Comprehensive Practice Center” with the School of Smart City at Beijing Union University. Leveraging its Extreme Flow platform, the Company supports algorithm teaching and research in universities, helping to cultivate AI talent.In the transportation and mobility sector, Extreme Vision has identified new application scenarios for large model solutions. Using large model technologies, the Company has generated autonomous driving simulation scenario data and conducted hallucination detection for a leading automotive retailer, helping the client reduce reliance on real-world road data collection and optimize the R&D process.These projects not only demonstrate the breadth and depth of Extreme Vision's technology implementation but also collectively underpin the Company's sustained growth. Each successfully delivered project generates experience and reusable modules for future projects, creating a virtuous cycle that contributes to a product repurchase rate of over 80%.Profitability Continuously Validated, Large Model Emerges as a New Growth DriverAs its commercial value continues to be validated, Extreme Vision's profitability has also shown strong growth momentum. The Company's revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate (CAGR) of 59.2%. The gross profit margin improved from 30.6% in 2022 to 40.2% in 2024. The Company recorded a profit of RMB8.71 million in 2024, making it one of the few profitable AI vision companies in China. For the nine months ended September 30, 2025, the Company achieved revenue of RMB136.3 million, a year-on-year increase of 71.7%, with the gross profit margin further rising to 44.9%.Notably, the large model solutions launched by the Company in 2024 contributed RMB62.12 million in revenue, accounting for 24.1% of total revenue. This has become a new growth driver and is expected to unlock further market opportunities.In terms of R&D investment, the Company continued to increase its efforts. R&D expenditure reached RMB44.82 million in 2024, an increase of 22.6% compared to 2023. As of September 30, 2025, the Company had a professional team of 101 R&D personnel. According to the Prospectus, the Company intends to use approximately 60.0% of the net proceeds from the IPO (HK$260.6 million) to enhance R&D capabilities, including the construction of large models and AI infrastructure, as well as the upgrade of AI-PaaS middleware.Broad Market Prospects: The Platform Flywheel AcceleratesIndustry prospects are promising. According to Frost & Sullivan, the market size of China’s emerging enterprise-level computer vision solutions is projected to grow from RMB11.1 billion in 2024 to RMB97.0 billion in 2029, representing a CAGR of 54.3%. This represents an almost eightfold increase in market size over the next five years, indicating strong inherent growth potential in the sector.As large models gain traction globally, market expectations for AI have been further elevated. However, in the B2B market, no matter how cutting-edge the technology is, it must ultimately return to the simple logic of “usability, practicality, and cost controllability.” Extreme Vision's experience shows that a competitive edge for AI companies lies not only in technological leadership but also in the ability to develop standardized solutions for complex industrial scenarios and scale them through platforms and ecosystems.From algorithms to applications, from project delivery to customer retention, Extreme Vision has remained committed to its mission of pushing technological boundaries and harnessing technology for good—building an AI flywheel that continuously generates commercial value. As AI technology permeates all industries, from industrial safety and energy inspection to retail operations, the demand for fragmented long-tail scenarios continues to emerge, positioning Extreme Vision for accelerated growth. However, whether it can continuously increase market share and improve cash flow amid fierce competition remains a core challenge post-listing. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.Return to Profitability Driven by Vaccine Portfolio GrowthAccording to its annual results, CanSinoBIO achieved total revenue of approximately RMB 1.068 billion, representing a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.9 million, marking a return to profitability.The turnaround reflects more than a cyclical rebound and suggests the company is building a more sustainable revenue base through the commercialization of routine vaccines. This has strengthened its ability to generate consistent cash flow.The improvement was driven primarily by organic growth in core operations rather than one-off factors. During the reporting period, the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (trade name: Menhycia(R)) maintained steady revenue growth, while its 13-valent Pneumococcal Conjugate Vaccine (trade name: iPneucia(R)) gained market traction following its launch. A more balanced revenue mix has improved earnings visibility.In addition, CanSinoBIO received multiple government grants and international R&D funding support during the year, reflecting recognition of its technological capabilities and innovative value.Core Products Set to Scale Up, Pipeline Supports Future GrowthBeyond near-term earnings, the company is supported by a diversified pipeline that provides both mid- and long-term growth drivers.As a core growth driver for CanSinoBIO, Menhycia(R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to expand its market reach. In February 2026, the company announced that the supplemental application to expand the age range of applicable population of Menhycia(R) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved, further broadening its target population.Meanwhile, iPneucia(R)—China’s first 13-valent pneumococcal conjugate vaccine using a dual-carrier system (CRM197 and tetanus toxoid)—is expected to generate commercial synergies with Menhycia(R). Shared distribution and marketing channels could help lower marginal sales costs and improve overall efficiency.In addition, the company’s mid-term pipeline remains robust. It’s absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the “DTcP”) for infants (below 2 years old) (the “DTcP Infant”)has been included in the priority review pathway, which will accelerate its approval timeline.To date, no component-based DTaP vaccine developed by domestic manufacturers has been approved for market launch in China. The infant DTcP vaccine is formulated with individually purified pertussis antigens in defined ratios to ensure consistent quality and stability. Its development also lays the groundwork for adolescent and adult component Tdap vaccines and combination vaccines, enhancing the Company’s product portfolio and core competitiveness.From near-term delivery to mid-term development and long-term innovation, CanSino Biologics’ value goes beyond its existing productsR&D Capabilities Support Long-Term CompetitivenessAs a leading innovative vaccine company, CanSinoBIO consistently adheres to a long-term strategy, ensuring the company remains at the forefront of technological exploration and laying a solid foundation for its sustained competitiveness.Its core talent team brings an average of more than 25 years of industry experience across global pharmaceutical and biotechnology companies, spanning research, manufacturing and commercialization. This has enabled the company to establish an integrated development system aligned with international standards and covering the full development cycle from early-stage research to commercialization.Over time, CanSinoBIO has also built five core technology platforms, including viral vector vaccines, synthetic vaccines, protein structure design and Virus-Like Particle (VLP) assembly, mRNA vaccines, and formulation and delivery technologies. These platforms support a diversified innovation system and provide a solid foundation for lifecycle vaccine development.The company continues to focus on differentiated innovation, including multivalent combination vaccines and novel delivery technologies, with the aim of developing globally competitive vaccine products.These technological capabilities have supported the launch of products like Menhycia(R) and iPneucia(R), reinforcing the company’s position in the vaccine sector.International Expansion Gains MomentumMeanwhile, amid intensifying competition in the domestic vaccine market, CanSinoBIO is accelerating its international expansion.Recently, the company announced that its manufacturing facility has passed the PIC/S GMP certification issued by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). PIC/S is an internationally recognized framework for pharmaceutical inspection and certification, comprising regulatory agencies from over 50 countries. This certification not only confirms that Menhycia(R) and iPneucia(R) meet international-quality standards but also enhances the company’s prospects for entering additional global markets.In fact, the Company’s international presence is well established, with Menhycia(R) obtaining Indonesian registration and Halal certification since 2024.The company has also entered into multiple strategic partnerships abroad, covering commercialization, joint R&D, clinical trials, and localized production. Through a “technology transfer + local manufacturing” approach, CanSinoBIO is expanding its presence beyond product exports toward broader technology-based collaboration.Growth Catalysts Point to Potential Re-RatingOverall, the latest results suggest CanSinoBIO is moving through an inflection point, supported by clearer commercialization pathways.Yet, its current market valuation may not fully reflect its investment potential. Looking ahead, potential growth drivers include the expanded indication for Menhycia(R), continued ramp-up in iPneucia(R) sales, the infant DTcP vaccine currently under priority review, as well as further international market expansion. At the same time, China’s policy support for biopharmaceuticals as a strategic sector could provide a favorable backdrop for valuation.As earnings continue to improve and market expectations adjust, the company may see both earnings growth and a re-rating in valuation multiples. Against the backdrop of China’s rising focus on biopharmaceutical innovation, CanSinoBIO’s long-term investment case is increasingly difficult to ignore. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com